Remove Clinic Remove Eczema Remove Safety
article thumbnail

MHRA Grants Marketing Authorization for LEO Pharma’s CHE Cream in Great Britain

The Dermatology Digest

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

article thumbnail

AD Pipeline Watch: Amgen, Kyowa Kirin’s Anti-OX40 Candidate Meets Endpoints in AD Trial

The Dermatology Digest

The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase (JAK) inhibitor medication. At week 24, 42.3%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Thinning Eyebrows in Women Over 40: Causes and Best Treatments

Alison Bladh

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Dermatology Clinics. Microblading: Safety and Efficacy in Eyebrow Enhancement. Clinical and Aesthetic Dermatology. Journal of Cosmetic Dermatology. Shapiro, J., & Maddin, S.

article thumbnail

More Breaking News: U.S. FDA Approves Nemolizumab (Nemluvio, Galderma) for Patients with Moderate to Severe AD

The Dermatology Digest

This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of nemolizumab in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 or older with moderate to severe atopic dermatitis.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

article thumbnail

AD Pipeline Update:Target Enrollment Complete in Phase 2b Trial of Nectar’s Rezpegaldesleukin in AD

The Dermatology Digest

Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Robin, President and CEO of Nektar Therapeutics, in a news release.

article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.